Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.

Judson I, Morden JP, Kilburn L, Leahy M, Benson C, Bhadri V, Campbell-Hewson Q, Cubedo R, Dangoor A, Fox L, Hennig I, Jarman K, Joubert W, Kernaghan S, López Pousa A, McNeil C, Seddon B, Snowdon C, Tattersall M, Toms C, Martinez Trufero J, Bliss JM.

Lancet Oncol. 2019 Jul;20(7):1023-1034. doi: 10.1016/S1470-2045(19)30215-3. Epub 2019 May 31.

2.

Early results and volumetric analysis after spot-scanning proton therapy with concomitant hyperthermia in large inoperable sacral chordomas.

Tran S, Puric E, Walser M, Poel R, Datta NR, Heuberger J, Pica A, Marder D, Lomax N, Bolsi A, Morach P, Bachtiary B, Seddon BM, Schneider R, Bodis S, Weber DC.

Br J Radiol. 2019 May 14:20180883. doi: 10.1259/bjr.20180883. [Epub ahead of print]

PMID:
30943055
3.

Survival of Single Positive Thymocytes Depends upon Developmental Control of RIPK1 Kinase Signaling by the IKK Complex Independent of NF-κB.

Webb LV, Barbarulo A, Huysentruyt J, Vanden Berghe T, Takahashi N, Ley S, Vandenabeele P, Seddon B.

Immunity. 2019 Feb 19;50(2):348-361.e4. doi: 10.1016/j.immuni.2019.01.004. Epub 2019 Feb 5.

4.

Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood.

Liu Z, Martin J, Orme L, Seddon B, Desai J, Nicholls W, Thomson D, Porter D, McCowage G, Underhill C, Cranswick N, Michael M, Zacharin M, Herschtal A, Sivasuthan J, Thomas DM.

Cancer Chemother Pharmacol. 2018 Nov;82(5):887-898. doi: 10.1007/s00280-018-3683-8. Epub 2018 Sep 11.

PMID:
30206658
5.

The natural history of naive T cells from birth to maturity.

Seddon B, Yates AJ.

Immunol Rev. 2018 Sep;285(1):218-232. doi: 10.1111/imr.12694. Review.

PMID:
30129206
6.

Age is not just a number: Naive T cells increase their ability to persist in the circulation over time.

Rane S, Hogan T, Seddon B, Yates AJ.

PLoS Biol. 2018 Apr 11;16(4):e2003949. doi: 10.1371/journal.pbio.2003949. eCollection 2018 Apr.

7.

IL-7-dependent maintenance of ILC3s is required for normal entry of lymphocytes into lymph nodes.

Yang J, Cornelissen F, Papazian N, Reijmers RM, Llorian M, Cupedo T, Coles M, Seddon B.

J Exp Med. 2018 Apr 2;215(4):1069-1077. doi: 10.1084/jem.20170518. Epub 2018 Feb 22.

8.

The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma.

Forker L, Gaunt P, Sioletic S, Shenjere P, Potter R, Roberts D, Irlam J, Valentine H, Hughes D, Hughes A, Billingham L, Grimer R, Seddon B, Choudhury A, Robinson M, West CML.

Br J Cancer. 2018 Mar 6;118(5):698-704. doi: 10.1038/bjc.2017.430. Epub 2017 Dec 12.

9.

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S.

Lancet Oncol. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4.

10.

Quantum Dot Nanotoxicity Investigations Using Human Lung Cells and TOXOR Electrochemical Enzyme Assay Methodology.

O'Hara T, Seddon B, O'Connor A, McClean S, Singh B, Iwuoha E, Fuku X, Dempsey E.

ACS Sens. 2017 Jan 27;2(1):165-171. doi: 10.1021/acssensors.6b00673. Epub 2017 Jan 5.

PMID:
28722443
11.

Validation of a membrane touch biosensor for the qualitative detection of IgG class antibodies to herpes simplex virus type 2.

Loughman T, Singh B, Seddon B, Noone P, Santhosh P.

Analyst. 2017 Jul 24;142(15):2725-2734. doi: 10.1039/c7an00666g.

PMID:
28708188
12.

UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).

Judson I, Bulusu R, Seddon B, Dangoor A, Wong N, Mudan S.

Clin Sarcoma Res. 2017 Apr 21;7:6. doi: 10.1186/s13569-017-0072-8. eCollection 2017.

13.

Memory CD4 T cell subsets are kinetically heterogeneous and replenished from naive T cells at high levels.

Gossel G, Hogan T, Cownden D, Seddon B, Yates AJ.

Elife. 2017 Mar 10;6. pii: e23013. doi: 10.7554/eLife.23013.

14.

UK guidelines for the management of soft tissue sarcomas.

Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I.

Clin Sarcoma Res. 2016 Nov 15;6:20. eCollection 2016. Review.

15.

Monogenic and polygenic determinants of sarcoma risk: an international genetic study.

Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM; International Sarcoma Kindred Study.

Lancet Oncol. 2016 Sep;17(9):1261-71. doi: 10.1016/S1470-2045(16)30147-4. Epub 2016 Aug 4.

PMID:
27498913
16.

TNF activation of NF-κB is essential for development of single-positive thymocytes.

Webb LV, Ley SC, Seddon B.

J Exp Med. 2016 Jul 25;213(8):1399-407. doi: 10.1084/jem.20151604. Epub 2016 Jul 18.

17.

Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group.

Foulon S, Brennan B, Gaspar N, Dirksen U, Jeys L, Cassoni A, Claude L, Seddon B, Marec-Berard P, Whelan J, Paulussen M, Streitbuerger A, Oberlin O, Juergens H, Grimer R, Le Deley MC.

Eur J Cancer. 2016 Jul;61:128-36. doi: 10.1016/j.ejca.2016.03.075. Epub 2016 May 10.

PMID:
27176931
18.

Follow-up practices for high-grade extremity Osteosarcoma.

Rothermundt C, Seddon BM, Dileo P, Strauss SJ, Coleman J, Briggs TW, Haile SR, Whelan JS.

BMC Cancer. 2016 May 6;16:301. doi: 10.1186/s12885-016-2333-y.

19.

First-line treatment in advanced or metastatic disease: one size fits all or adapted to specific histiotypes?

Seddon B.

Curr Opin Oncol. 2016 Jul;28(4):323-30. doi: 10.1097/CCO.0000000000000301. Review.

PMID:
27153355
20.

UK guidelines for the management of bone sarcomas.

Gerrand C, Athanasou N, Brennan B, Grimer R, Judson I, Morland B, Peake D, Seddon B, Whelan J; British Sarcoma Group.

Clin Sarcoma Res. 2016 May 4;6:7. doi: 10.1186/s13569-016-0047-1. eCollection 2016. Review.

21.

IL-4-producing ILC2s are required for the differentiation of TH2 cells following Heligmosomoides polygyrus infection.

Pelly VS, Kannan Y, Coomes SM, Entwistle LJ, Rückerl D, Seddon B, MacDonald AS, McKenzie A, Wilson MS.

Mucosal Immunol. 2016 Nov;9(6):1407-1417. doi: 10.1038/mi.2016.4. Epub 2016 Feb 17.

22.

ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation.

Pearson C, Thornton EE, McKenzie B, Schaupp AL, Huskens N, Griseri T, West N, Tung S, Seddon BP, Uhlig HH, Powrie F.

Elife. 2016 Jan 18;5:e10066. doi: 10.7554/eLife.10066.

23.

Temporal fate mapping reveals age-linked heterogeneity in naive T lymphocytes in mice.

Hogan T, Gossel G, Yates AJ, Seddon B.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):E6917-26. doi: 10.1073/pnas.1517246112. Epub 2015 Nov 25.

24.

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators.

J Clin Oncol. 2015 Jul 10;33(20):2279-87. doi: 10.1200/JCO.2014.60.0734. Epub 2015 Jun 1. Erratum in: J Clin Oncol. 2016 Nov 20;34(33):4059.

25.

A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.

Seddon B, Scurr M, Jones RL, Wood Z, Propert-Lewis C, Fisher C, Flanagan A, Sunkersing J, A'Hern R, Whelan J, Judson I.

Clin Sarcoma Res. 2015 May 16;5:13. doi: 10.1186/s13569-015-0029-8. eCollection 2015.

26.

Clinical outcome in patients with peripherally-sited atypical lipomatous tumours and dedifferentiated liposarcoma.

Kalimuthu SN, Tilley C, Forbes G, Ye H, Lehovsky K, Pillay N, Seddon BM, O'Donnell P, Pollock R, Tirabosco R, Amary MF, Flanagan AM.

J Pathol Clin Res. 2015 Mar 16;1(2):106-12. doi: 10.1002/cjp2.12. eCollection 2015 Apr.

27.

Thymic IL-7 signaling goes beyond survival.

Seddon B.

Nat Immunol. 2015 Apr;16(4):337-8. doi: 10.1038/ni.3128. No abstract available.

PMID:
25789675
28.

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.

Reichardt P, Kang YK, Rutkowski P, Schuette J, Rosen LS, Seddon B, Yalcin S, Gelderblom H, Williams CC Jr, Fumagalli E, Biasco G, Hurwitz HI, Kaiser PE, Fly K, Matczak E, Chen L, Lechuga MJ, Demetri GD.

Cancer. 2015 May 1;121(9):1405-13. doi: 10.1002/cncr.29220. Epub 2015 Jan 13. Erratum in: Cancer. 2019 Mar 1;125(5):821.

29.

A Zap70-dependent feedback circuit is essential for efficient selection of CD4 lineage thymocytes.

Sinclair C, Ono M, Seddon B.

Immunol Cell Biol. 2015 Apr;93(4):406-16. doi: 10.1038/icb.2014.107. Epub 2015 Jan 20.

PMID:
25601273
30.

Differential requirement for IL-2 and IL-15 during bifurcated development of thymic regulatory T cells.

Marshall D, Sinclair C, Tung S, Seddon B.

J Immunol. 2014 Dec 1;193(11):5525-33. doi: 10.4049/jimmunol.1402144. Epub 2014 Oct 27.

31.

Spatial heterogeneity and peptide availability determine CTL killing efficiency in vivo.

Hogan T, Kadolsky U, Tung S, Seddon B, Yates A.

PLoS Comput Biol. 2014 Sep 18;10(9):e1003805. doi: 10.1371/journal.pcbi.1003805. eCollection 2014 Sep.

32.

Zap70 is essential for long-term survival of naive CD8 T cells.

Schim van der Loeff I, Hsu LY, Saini M, Weiss A, Seddon B.

J Immunol. 2014 Sep 15;193(6):2873-80. doi: 10.4049/jimmunol.1400858. Epub 2014 Aug 4.

33.

Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.

Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S67-72. doi: 10.1097/IGC.0000000000000205. Review.

PMID:
25033257
34.

Microwave ablation of pulmonary metastases associated with perioperative takotsubo cardiomyopathy.

Best L, Seddon B, Woldman S, Lyon A, Illing R.

J Vasc Interv Radiol. 2014 Jul;25(7):1139-41. doi: 10.1016/j.jvir.2014.04.001. No abstract available.

PMID:
24968728
35.

Overlapping and asymmetric functions of TCR signaling during thymic selection of CD4 and CD8 lineages.

Sinclair C, Seddon B.

J Immunol. 2014 Jun 1;192(11):5151-9. doi: 10.4049/jimmunol.1303085. Epub 2014 Apr 25.

36.

What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients.

Rothermundt C, Whelan JS, Dileo P, Strauss SJ, Coleman J, Briggs TW, Haile SR, Seddon BM.

Br J Cancer. 2014 May 13;110(10):2420-6. doi: 10.1038/bjc.2014.200. Epub 2014 Apr 15.

37.

Parameter identification for model of T cell proliferation in lymphopenia conditions.

Ayoub H, Ainseba BE, Langlais M, Hogan T, Callard R, Seddon B, Thiébaut R.

Math Biosci. 2014 May;251:63-71. doi: 10.1016/j.mbs.2014.03.002. Epub 2014 Mar 12.

PMID:
24631178
38.

NF-κB signaling mediates homeostatic maturation of new T cells.

Silva A, Cornish G, Ley SC, Seddon B.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):E846-55. doi: 10.1073/pnas.1319397111. Epub 2014 Feb 18.

39.

Tumour volume changes following pre-operative radiotherapy in borderline resectable limb and trunk soft tissue sarcoma.

le Grange F, Cassoni AM, Seddon BM.

Eur J Surg Oncol. 2014 Apr;40(4):394-401. doi: 10.1016/j.ejso.2014.01.011. Epub 2014 Feb 2.

PMID:
24534361
40.

Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.

Kollàr A, Maruzzo M, Messiou C, Cartwright E, Miah A, Martin-Liberal J, Thway K, McGrath E, Dunlop A, Khabra K, Seddon B, Dileo P, Linch M, Judson I, Benson C.

Clin Sarcoma Res. 2014 Dec 4;4:17. doi: 10.1186/2045-3329-4-17. eCollection 2014.

41.

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.

Gelderblom H, Blay JY, Seddon BM, Leahy M, Ray-Coquard I, Sleijfer S, Kerst JM, Rutkowski P, Bauer S, Ouali M, Marreaud S, van der Straaten RJ, Guchelaar HJ, Weitman SD, Hogendoorn PC, Hohenberger P.

Eur J Cancer. 2014 Jan;50(2):388-96. doi: 10.1016/j.ejca.2013.10.002. Epub 2013 Nov 8.

PMID:
24215845
42.

Models of self-peptide sampling by developing T cells identify candidate mechanisms of thymic selection.

Bains I, van Santen HM, Seddon B, Yates AJ.

PLoS Comput Biol. 2013;9(7):e1003102. doi: 10.1371/journal.pcbi.1003102. Epub 2013 Jul 25.

43.

Asymmetric thymocyte death underlies the CD4:CD8 T-cell ratio in the adaptive immune system.

Sinclair C, Bains I, Yates AJ, Seddon B.

Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):E2905-14. doi: 10.1073/pnas.1304859110. Epub 2013 Jul 15.

44.

Regulation of asymmetric cell division and polarity by Scribble is not required for humoral immunity.

Hawkins ED, Oliaro J, Kallies A, Belz GT, Filby A, Hogan T, Haynes N, Ramsbottom KM, Van Ham V, Kinwell T, Seddon B, Davies D, Tarlinton D, Lew AM, Humbert PO, Russell SM.

Nat Commun. 2013;4:1801. doi: 10.1038/ncomms2796.

PMID:
23653213
45.

Clonally diverse T cell homeostasis is maintained by a common program of cell-cycle control.

Hogan T, Shuvaev A, Commenges D, Yates A, Callard R, Thiebaut R, Seddon B.

J Immunol. 2013 Apr 15;190(8):3985-93. doi: 10.4049/jimmunol.1203213. Epub 2013 Mar 8.

46.

Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing's and other Small Round Cell Sarcomas.

Whelan J, Khan A, Sharma A, Rothermundt C, Dileo P, Michelagnoli M, Seddon B, Strausss S.

Clin Sarcoma Res. 2012 Sep 21;2(1):12. doi: 10.1186/2045-3329-2-12.

47.

Interleukin-7 influences FOXP3+CD4+ regulatory T cells peripheral homeostasis.

Simonetta F, Gestermann N, Martinet KZ, Boniotto M, Tissières P, Seddon B, Bourgeois C.

PLoS One. 2012;7(5):e36596. doi: 10.1371/journal.pone.0036596. Epub 2012 May 7.

48.

Exogenous amino acids are essential for interleukin-7 induced CD8 T cell growth. [corrected].

Pearson C, Silva A, Seddon B.

PLoS One. 2012;7(4):e33998. doi: 10.1371/journal.pone.0033998. Epub 2012 Apr 17. Erratum in: PLoS One. 2012;7(8). doi: 10.1371/annotation/ee9c3e82-855f-42e0-8e57-83981bc1ba16.

49.

Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where?

Haas RL, Delaney TF, O'Sullivan B, Keus RB, Le Pechoux C, Olmi P, Poulsen JP, Seddon B, Wang D.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):572-80. doi: 10.1016/j.ijrobp.2012.01.062. Epub 2012 Apr 18. Review.

PMID:
22520481
50.

Tissue specific deletion of inhibitor of kappa B kinase 2 with OX40-Cre reveals the unanticipated expression from the OX40 locus in skin epidermis.

Cornish GH, Tung SL, Marshall D, Ley S, Seddon BP.

PLoS One. 2012;7(2):e32193. doi: 10.1371/journal.pone.0032193. Epub 2012 Feb 21.

Supplemental Content

Loading ...
Support Center